Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronavirus Infections | 8 | 2020 | 72 | 1.380 |
Why?
|
| Pneumonia, Viral | 8 | 2020 | 77 | 1.370 |
Why?
|
| Intubation, Intratracheal | 3 | 2021 | 70 | 1.000 |
Why?
|
| Hospitalization | 6 | 2022 | 417 | 0.860 |
Why?
|
| Lung | 3 | 2016 | 233 | 0.710 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2016 | 37 | 0.530 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 88 | 0.520 |
Why?
|
| Nicotine | 1 | 2016 | 157 | 0.470 |
Why?
|
| Personnel, Hospital | 2 | 2020 | 12 | 0.390 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 9 | 0.390 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 55 | 0.380 |
Why?
|
| Recovery of Function | 2 | 2020 | 190 | 0.330 |
Why?
|
| Respiratory Insufficiency | 2 | 2019 | 61 | 0.330 |
Why?
|
| Adult | 17 | 2022 | 8441 | 0.330 |
Why?
|
| Humans | 24 | 2022 | 29147 | 0.310 |
Why?
|
| Vaccination | 3 | 2021 | 123 | 0.280 |
Why?
|
| Female | 18 | 2022 | 18189 | 0.270 |
Why?
|
| United States | 10 | 2022 | 3636 | 0.270 |
Why?
|
| Middle Aged | 15 | 2022 | 10846 | 0.270 |
Why?
|
| Acute Lung Injury | 2 | 2015 | 30 | 0.260 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 43 | 0.250 |
Why?
|
| Male | 17 | 2022 | 17832 | 0.240 |
Why?
|
| Outpatients | 2 | 2021 | 49 | 0.230 |
Why?
|
| Critical Illness | 2 | 2021 | 87 | 0.230 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 96 | 0.230 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 9 | 0.210 |
Why?
|
| Laryngoscopy | 1 | 2021 | 39 | 0.210 |
Why?
|
| Telecommunications | 1 | 2020 | 5 | 0.200 |
Why?
|
| Work | 1 | 2020 | 7 | 0.200 |
Why?
|
| Contact Tracing | 1 | 2020 | 8 | 0.190 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 5 | 0.190 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 31 | 0.190 |
Why?
|
| Shock | 1 | 2020 | 28 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 78 | 0.180 |
Why?
|
| Inpatients | 1 | 2020 | 64 | 0.180 |
Why?
|
| Beta vulgaris | 1 | 2019 | 11 | 0.180 |
Why?
|
| Environmental Exposure | 1 | 2020 | 87 | 0.180 |
Why?
|
| Length of Stay | 2 | 2019 | 292 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2020 | 97 | 0.180 |
Why?
|
| Nitrates | 1 | 2019 | 25 | 0.180 |
Why?
|
| Influenza, Human | 1 | 2021 | 122 | 0.180 |
Why?
|
| Aged | 9 | 2022 | 9494 | 0.180 |
Why?
|
| Case-Control Studies | 4 | 2021 | 859 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 142 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 33 | 0.160 |
Why?
|
| Lipopolysaccharides | 2 | 2015 | 107 | 0.160 |
Why?
|
| Vaccines, Synthetic | 3 | 2021 | 11 | 0.150 |
Why?
|
| Survivors | 1 | 2019 | 145 | 0.150 |
Why?
|
| Young Adult | 5 | 2021 | 2406 | 0.150 |
Why?
|
| Adolescent | 5 | 2021 | 3257 | 0.140 |
Why?
|
| Pregnancy | 2 | 2016 | 815 | 0.140 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.130 |
Why?
|
| Azacitidine | 1 | 2015 | 28 | 0.130 |
Why?
|
| Quality of Life | 1 | 2021 | 817 | 0.130 |
Why?
|
| Pneumonia | 1 | 2015 | 61 | 0.130 |
Why?
|
| Animals, Newborn | 1 | 2015 | 111 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 162 | 0.120 |
Why?
|
| Time Factors | 4 | 2021 | 2001 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2016 | 599 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3105 | 0.110 |
Why?
|
| Brain | 1 | 2020 | 930 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2011 | 6 | 0.100 |
Why?
|
| Inflammation | 2 | 2015 | 508 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2011 | 45 | 0.100 |
Why?
|
| Calcitonin | 1 | 2010 | 2 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2010 | 22 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 92 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 64 | 0.090 |
Why?
|
| Neutrophils | 1 | 2010 | 102 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 150 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2021 | 118 | 0.090 |
Why?
|
| Cytokines | 1 | 2010 | 243 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 464 | 0.080 |
Why?
|
| Logistic Models | 2 | 2021 | 727 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2021 | 2021 | 0.070 |
Why?
|
| Adoptive Transfer | 2 | 2015 | 16 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 864 | 0.060 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2015 | 18 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 711 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 3537 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 12 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 1306 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 980 | 0.050 |
Why?
|
| Health Facilities | 1 | 2021 | 11 | 0.050 |
Why?
|
| Trachea | 1 | 2021 | 55 | 0.050 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 4 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 9 | 0.050 |
Why?
|
| Antimalarials | 1 | 2020 | 6 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2020 | 13 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2020 | 159 | 0.050 |
Why?
|
| Cross Infection | 1 | 2020 | 46 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 165 | 0.050 |
Why?
|
| Nitrites | 1 | 2019 | 20 | 0.050 |
Why?
|
| Disease Progression | 1 | 2021 | 572 | 0.040 |
Why?
|
| Subacute Care | 1 | 2019 | 11 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 239 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 391 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 60 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 641 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 293 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 504 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2019 | 170 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 473 | 0.040 |
Why?
|
| Critical Care | 1 | 2019 | 114 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 631 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 26 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 871 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2015 | 30 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 50 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 67 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 49 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 47 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 425 | 0.030 |
Why?
|
| Monocytes | 1 | 2015 | 119 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 629 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 7300 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 799 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2011 | 13 | 0.030 |
Why?
|
| Baltimore | 1 | 2011 | 49 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 8 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 174 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 41 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2010 | 28 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 287 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 426 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 248 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 186 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2010 | 225 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 200 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 637 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 542 | 0.020 |
Why?
|
| Sepsis | 1 | 2010 | 147 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2371 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3112 | 0.010 |
Why?
|